NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Nectero Therapeutics

Nectero Therapeutics

Private
Tempe, ArizonaHealthcare & Life Scienceshttps://necterotherapeutics.com/

Last Round

Series D

Apr 11, 2024

Est. Valuation

$170M

Total Funding Raised

$211.5M

Company Overview

Nectero Therapeutics is a clinical-stage biotechnology company developing a novel treatment to stabilize growth and prevent rupture of mid-sized abdominal aortic aneurysms.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Keywords

abdominal aortic aneurysmAAAendovascular treatmentvascular surgeryminimally invasive surgerymedical devicepentagalloyl glucosePGGbiotechaneurysm repairendovascular devicevascular healthclinical-stage biotechinterventional cardiology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Nectero Therapeutics Comparables

Compare Nectero Therapeutics with similar companies based on industry and business-model similarity.

Nectero Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap

View Full Comparables Set

Access detailed peer comparisons, similarity scores, and market data.

Nectero Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series DApr 11, 2024
Series DJan 18, 2024
Series CSep 10, 2021
Series BApr 30, 2020

Nectero Therapeutics Investors

Notable investors and investment history

Nectero Therapeutics investors
InvestorRounds
Aphelion CapitalSeries D
Cadence MedTech VenturesSeries D
Cadence Healthcare VenturesSeries D
Norwest Venture PartnersSeries D
Boston Scientific CorporationSeries D, Series C
BioStar CapitalSeries D

Nectero Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Nectero Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Nectero Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersTempe, Arizona
Year Founded2017
Last FundingApr 11, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.